Aarkstore - Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

1
Aarkstore - Metastatic Hormone Refractory
(Castration Resistant, Androgen-Independent)
Prostate Cancer-Global API Manufacturers,
Marketed and Phase III Drugs Landscape, 2015
Category Pharmaceuticals and Healthcare
2
Metastatic Hormone Refractory (Castration
Resistant, Androgen-Independent) Prostate
Cancer-Global API Manufacturers, Marketed and
Phase III Drugs Landscape, 2015, Report provides
comprehensive insights about phase III pipeline
drugs and marketed drugs across the Metastatic
Hormone Refractory (Castration Resistant,
Androgen-Independent) Prostate Cancer. A key
objective of DelveInsights report is to establish
the understanding for API Manufacturers for
marketed and Phase III Pipeline drugs across the
different countries and regions for the drugs
falling under Metastatic Hormone Refractory
(Castration Resistant, Androgen-Independent)
Prostate Cancer. The Report gives insights into
patents providing the patent protection data and
marketing exclusivity of all the drugs across the
Metastatic Hormone Refractory (Castration
Resistant, Androgen-Independent) Prostate Cancer.
Browse Complete Report http//www.aarkstore.com
/pharmaceuticals-healthcare/98051/metastatic-hormo
ne-refractory-castration-resistant-androgen-indepe
ndent-prostate-cancer-global-api-manufacturers-mar
keted-and-phase-iii-drugs-landscape-20155
3
Data Sources

• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.
• Secondary sources information and data has been
  collected from various printable and
  non-printable sources like search engines, News
  websites, Government Websites, Trade Journals,
  White papers, Magazines, Trade associations,
  Books, Industry Portals, Industry Associations
  and access to available databases.
• Please noteThis report requires certain updates.
  We have all the information available but require
  3 business days to complete the process and
  ensure it is as up-to-date as possible. Certain
  sections in the report may be removed or altered
  based on the availability and relevance of data
  for the indicated disease.
• .

4
Scope

• A snapshot of the global Market therapeutics
  scenario for Metastatic Hormone Refractory
  (Castration Resistant, Androgen-Independent)
  Prostate Cancer.
• A review of the marketed products under
  prescription for Metastatic Hormone Refractory
  (Castration Resistant, Androgen-Independent)
  Prostate Cancer, regulatory information and
  marketing status.
• Coverage of global patent coverage and detailed
  commentaries on the US patent challenges.
• Graphical representation of investigational
  products for patent expiry and market
  exclusivities across the globe.
• Product profiles for marketed products for
  Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  with complete description of mechanism of action,
  therapeutic class, target, route(s) of
  administration and chemical details.
• Coverage of API Manufacturers for Metastatic
  Hormone Refractory (Castration Resistant,
  Androgen-Independent) Prostate Cancer drugs in
  the United States, Europe and Asian Regions with
  location details.

5
Reasons to buy

• A snapshot of the global Market therapeutics
  scenario for Metastatic Hormone Refractory
  (Castration Resistant, Androgen-Independent)
  Prostate Cancer.
• A review of the marketed products under
  prescription for Metastatic Hormone Refractory
  (Castration Resistant, Androgen-Independent)
  Prostate Cancer, regulatory information and
  marketing status.
• Coverage of global patent coverage and detailed
  commentaries on the US patent challenges.
• Graphical representation of investigational
  products for patent expiry and market
  exclusivities across the globe.
• Product profiles for marketed products for
  Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  with complete description of mechanism of action,
  therapeutic class, target, route(s) of
  administration and chemical details.

6
Table of Content

• Indication Overview
• Marketed Drugs
• Marketed Details of Drugs by Application Type
• Marketed Details of Drugs (NDA) by Marketing
  Status
• Marketed Details of Drugs by Patent Expiration
  Timeline
• Active Pharmaceutical Ingredient (API)
  Manufacturers Assessment
• API Manufacturers by United States Drug Master
  File (US DMF) Status
• API Manufacturers by US DMF Status (Drug
  Specific)
• API Manufacturers in Europe by Country
• API Manufacturers in India by State
• API Manufacturers in China by Province
• Marketed Details of Approved Drugs by Geography
• Active Pharmaceutical Ingredient (API)
  Manufacturers Assessment for Phase III Pipeline
  Drugs

7
List of Tables

• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Therapeutic Market, US, Marketed Drugs by
  Application Type, 2015
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Therapeutic Market, US, Marketed Drugs by
  Marketing Status, 2015
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Therapeutic Market, US, (Year), 2015
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Marketed Drugs, API Manufacturers by US DMF
  Status, 2015
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Marketed Drugs, US DMF Status Drug Specific
  (Number), 2015
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Drugs, API Manufacturers, Europe by Country, 2015
•  
•  

8
List of Figures

• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Therapeutic Market, US, Marketed Drugs by
  Application Type (), 2015
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Therapeutic Market, US, Marketed Drugs by
  Marketing Status (), 2015
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Therapeutic Market, US, (Year), 2015
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Marketed Drugs, API Manufacturers by US DMF
  Status (), 2015
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate Cancer
  Marketed Drugs, US DMF Status Drug Specific
  (Number), 2015

9
Related reports

•  
• Pharmaceutical Industry Business Confidence
  Report H1 2015
• Steatohepatitis Global Clinical Trials Review,
  H1, 2015
• Post Operative Nausea And Vomiting Global
  Clinical Trials Review, H1, 2015
• Nonerosive Reflux Disease (NERD) Global Clinical
  Trials Review, H1, 2015
• Nonerosive Reflux Disease (NERD) Global Clinical
  Trials Review, H1, 2015
• Non Alcoholic Fatty Liver Disease (NAFLD) Global
  Clinical Trials Review, H1, 2015
• Patient Monitoring and Diagnostic Systems Markets
  in China
• Hearing Aids Markets in China
• Medical Imaging System and Equipment Markets in
  China
• Medical Devices Markets in China

10

• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate
  Cancer-Global API Manufacturers, Marketed and
  Phase III Drugs Landscape, 2015
• Published Feb 2015 100 Pages
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate
  Cancer-Global API Manufacturers, Marketed and
  Phase III Drugs Landscape, 2015, Report provides
  comprehensive insights about phase III pipeline
  drugs and marketed drugs across the Metastatic
  Hormone Refractory (Castration Resistant,
  Androgen-Independent) Prostate Cancer.
• Price

Format Price
PDF 2000
Site License 4000
Enterprise Wide License 6000
11
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news